Jim joined New Enterprise Associates (NEA) in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Present board memberships include Eximias Pharmaceutical Corporation, GlycoMimetics, Inhibitex, Inc. (NASDAQ: INHX), Iomai Corporation ("IOMI"), Nucleonics, Inc., Peptimmune, Inc., Pharmion Corporation (NASDAQ: PHRM), Ruxton Pharmaceuticals, Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals and Targacept. Inc. He also served on the board of MedImmune. Prior to NEA, Jim served as Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995), President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Jim worked in various divisions of SmithKline. NEA and Jim have worked together since 1982 when he was recruited to run Bethesda Research Laboratories, which merged with Life Technologies. NEA then backed Jim at Genetic Therapy and later at Sensors for Medicine and Science. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.